Watson Pharmaceuticals’ TRELSTAR receives FDA approval for treatment of advanced prostate cancer
March 15, 2010 by Prostate Dr.
Multimedia software program developed to help prostate cancer patients make treatment decisions
Mount Sinai School of Medicine is leading a study of patients newly-diagnosed with prostate cancer to determine if providing them with multimedia materials can help them make more informed treatment decisions. Michael Diefenbach, Ph.D., Associate Professor of Urology at Mount Sinai School of Medicine developed a multimedia software program designed to help prostate cancer patients and their …
Read more on News-Medical-Net
Watson Pharmaceuticals’ TRELSTAR receives FDA approval for treatment of advanced prostate cancer
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Read more on News-Medical-Net
Related prostate health articles:
- None Found
Comments